...
首页> 外文期刊>Veterinary and Comparative Oncology >Piroxicam and carboplatin as a combination treatment of canine oral non-tonsillar squamous cell carcinoma: a pilot study and a literature review of a canine model of human head and neck squamous cell carcinoma
【24h】

Piroxicam and carboplatin as a combination treatment of canine oral non-tonsillar squamous cell carcinoma: a pilot study and a literature review of a canine model of human head and neck squamous cell carcinoma

机译:吡罗昔康和卡铂联合治疗犬口腔非扁桃体鳞状细胞癌:人头颈部鳞状细胞癌犬模型的初步研究和文献综述

获取原文
获取原文并翻译 | 示例
           

摘要

Results of the treatment with a combination of carboplatin and piroxicam in seven dogs with advanced non-tonsillar oral squamous cell carcinoma (SCC) were retrospectively, analysed. This multi-agent protocol was well tolerated by all dogs and resultedin a complete regression of the tumour without additional surgery in four of seven patients. Additional surgery was necessary to remove a metastatic lymph node in one dog and residual tumour in a second dog, which achieved a partial response following medical therapy. Median follow-up for all the dogs was 534 days, while the time-to-recurrence, time-to-progression and overall survival for this group of patients have not yet been reached, Our study, although limited in number of animals, suggests that this multiagent approach is a useful treatment option for oral non-tonsillarSCC in dogs and warrants wider application.
机译:回顾性分析了卡铂和吡罗昔康联合治疗7例晚期非扁桃体口腔鳞状细胞癌(SCC)犬的治疗结果。所有狗都很好地耐受了这种多药物治疗方案,并且在七名患者中有四名患者无需额外手术即可完全消退肿瘤。必须进行额外的手术以去除一只狗的转移性淋巴结和另一只狗的残留肿瘤,在药物治疗后达到部分反应。所有犬只的中位随访时间为534天,但尚未达到该组患者的复发时间,进展时间和总体存活率。尽管动物数量有限,我们的研究表明这种多药物治疗方法是犬口服非扁桃体鳞癌的有用治疗选择,值得广泛应用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号